Holen Sie sich die Stockscreener-App
40.92
1.38%
-0.5357
Schlusskurs vom Vortag:
$41.46
Offen:
$41.41
24-Stunden-Volumen:
207.97K
Relative Volume:
0.40
Marktkapitalisierung:
$1.97B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+9.71%
1M Leistung:
+42.96%
6M Leistung:
+219.18%
1J Leistung:
+0.00%
1-Tages-Spanne:
$40.54
$41.80
1-Wochen-Bereich:
$37.45
$43.29
52-Wochen-Spanne:
$6.71
$43.29
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
40.92 | 2.00B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ
Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat
Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada
A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - Setenews
MAZE Crosses Above Average Analyst Target - Nasdaq
Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada
HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView
What dividend safety score for Maze Therapeutics Inc. stockMarket Sentiment Report & Technical Confirmation Trade Alerts - moha.gov.vn
How Maze Therapeutics Inc. stock benefits from tech adoption2025 Geopolitical Influence & Weekly Setup with High ROI Potential - BỘ NỘI VỤ
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4%Should You Buy? - MarketBeat
Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Is Maze Therapeutics Inc. stock recession proofJuly 2025 PostEarnings & Safe Capital Investment Plans - newser.com
Maze Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Heatmap analysis for Maze Therapeutics Inc. and competitorsLong Setup & Consistent Income Trade Ideas - newser.com
Will Maze Therapeutics Inc. stock deliver consistent dividendsStock Surge & AI Based Buy and Sell Signals - newser.com
Applying chart zones and confluence areas to Maze Therapeutics Inc.Entry Point & Long-Term Safe Return Strategies - newser.com
Can you recover from losses in Maze Therapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Is Maze Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Will Maze Therapeutics Inc. outperform the marketOptions Play & High Win Rate Trade Tips - newser.com
How institutional buying supports Maze Therapeutics Inc. stock2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):